The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.
Adult
Aged
Aged, 80 and over
Aniline Compounds
/ blood
Antineoplastic Agents
/ adverse effects
Dasatinib
/ blood
Female
Humans
Japan
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ complications
Liver Cirrhosis
/ physiopathology
Male
Middle Aged
Nitriles
/ blood
Protein Kinase Inhibitors
/ blood
Quinolines
/ blood
Renal Dialysis
Renal Insufficiency
/ physiopathology
Treatment Outcome
bosutinib
dasatinib
hemodialysis
liver cirrhosis
plasma concentrations
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
pubmed:
10
7
2020
medline:
23
3
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.
Identifiants
pubmed: 32641651
doi: 10.2169/internalmedicine.4871-20
pmc: PMC7691019
doi:
Substances chimiques
Aniline Compounds
0
Antineoplastic Agents
0
Nitriles
0
Protein Kinase Inhibitors
0
Quinolines
0
bosutinib
5018V4AEZ0
Dasatinib
RBZ1571X5H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2745-2749Références
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Clin Pharmacol Ther. 2003 May;73(5):427-34
pubmed: 12732843
J Am Soc Nephrol. 2001 Feb;12(2):326-32
pubmed: 11158222
J Am Soc Nephrol. 2002 Jun;13(6):1579-85
pubmed: 12039987
Case Rep Gastroenterol. 2016 May 19;10(1):17-23
pubmed: 27403097
Int J Hematol. 2020 Jul;112(1):115-117
pubmed: 32152879
Eur J Clin Pharmacol. 2013 Apr;69(4):813-23
pubmed: 23052406
Cancer Chemother Pharmacol. 2013 Jan;71(1):123-32
pubmed: 23053269
Intern Med. 2012;51(12):1561-5
pubmed: 22728491
Cancer Chemother Pharmacol. 2005 Oct;56(4):358-60
pubmed: 15883819
Leuk Res. 2009 Feb;33(2):344-7
pubmed: 18835038
Blood. 2015 Jul 2;126(1):42-9
pubmed: 25918346
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):275-285.e1
pubmed: 27013180
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Am J Hematol. 2012 Apr;87(4):451
pubmed: 22407703
Leuk Res. 2016 Sep;48:84-91
pubmed: 27505637
Am J Hematol. 2006 Jun;81(6):474
pubmed: 16680756
Leuk Lymphoma. 2011 Jun;52(6):1024-9
pubmed: 21463107
Clin Pharmacol. 2013 Jun 10;5:85-97
pubmed: 23788844